AVANIR Pharmaceuticals, Inc.
AVANIR Provides Clinical and Corporate Updates
Published in Food and Drug Law Weekly, April 17th, 2009
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today provided an update on the STAR trial and announced that it has completed additional pre-clinical and clinical studies to enhance the complete response to the approvable letter for the new lower dose Zenvia™ (dextromethorphan 30mg/quinidine 10mg [DM/Q 30/10]) formulation. The Company has also announced that the NASDAQ exchange has extended the temporary suspension of bid price requirements, which is expected to permit the continued listing of the Company’s Common Stock on the NASDAQ Global Market until at least November 13, 2009. STAR TRIAL UPDATE Earlier in March, AVANIR announced it had achieved targeted enrollment of approximately 300...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- Center for Justice & Democracy
Consumer Group Releases New Study About Defective Heart Devices and Implants; Patients Arrive in DC Tomorrow - HiFi DNA Tech
Recently Approved HPV Test May Prompt Unnecessary Surgical Biopsies on Women: HiFi DNA Seeks Transparency of “Results” from the FDA and Scientific Data on Newly Approved Human Papillomavirus HPV Tests - Office of the Speaker of the House
Pelosi on House Passage of Bill Granting FDA Authority to Regulate Tobacco - Patents
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents - Pharmaceuticals
China Shenghuo Reports Year 2008 Financial Results - Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
